Pathios Therapeutics welcomes Dr. Jeanmarie Guenot to its Board as Non-Executive Director

– UK, Milton –  Pathios Therapeutics Limited, a biotech company focused on developing first-in-class therapies for cancer, today announced the appointment of Dr. Jeanmarie Guenot (Ph.D.) to its Board as a non-executive director, bringing more than 30 years of experience in the pharmaceutical and biotechnology industries, having worked in venture capital, as well as at public and private companies in roles spanning executive management, corporate development, and research and development.

“We are delighted to welcome Jeanmarie to Pathios to help us to deliver on the promise of targeting GPR65 as a critical innate immune checkpoint in solid tumours. Her extensive experience in both corporate management and R&D leadership make her perfectly suited to support Pathios in the next phase of our mission to advance our GPR65 small-molecule inhibitors toward clinical development,” said CEO, Dr. Stuart Hughes.

About Dr. Jeanmarie Guenot

Dr. Guenot is currently the Founder, President, and CEO of Toreador Therapeutics, a preclinical stage company discovering and developing bispecific antibody therapeutics for the treatment of cancer. In 2013, she founded Amphivena Therapeutics and served as the company’s President and CEO through the end of 2019. During her time with Amphivena, Dr. Guenot oversaw the closing of a $62 million Series C financing, as well as the advancement of the company’s lead therapeutic candidate, a novel T cell engager in clinical trials for acute myeloid leukemia and myelodysplastic syndrome, into Phase 1 clinical trials for the treatment of solid tumors. In 2015, while still leading Amphivena, she founded and became the President and CEO of Harpoon Therapeutics, a company developing half-life extended and conditionally-activated T-cell engagement therapeutics for the treatment of cancer. In 2016, Dr. Guenot spun out Maverick Therapeutics from Harpoon and executed a strategic build-to-buy transaction with Takeda. This deal, which included a $125 million upfront option and R&D funding, and up to $525 million in option exercise and earnouts, was exercised in 2021.

“I am honored to join the board of Pathios Therapeutics and help support the ground-breaking science the company is advancing in immune checkpoint inhibitors. The company has already compiled a compelling preclinical data package for its small molecule inhibitors of GPR65 that offers a strong rationale for advancing the program into the clinic to address major unmet medical needs for cancer patients,” said Dr. Guenot. “I look forward to working with the Pathios board and executive team at this pivotal time. I am excited to contribute to the continued development of the company’s first-in-class therapies.”

About Pathios Therapeutics

Pathios is a drug discovery and development company focused on translating innovative science into new medicines. Pathios was founded by a team of experienced biotech and pharmaceutical industry professionals, entrepreneurs, and clinicians. Pathios is focused on developing small-molecule inhibitors of the pH-sensing G protein-coupled receptor GPR65 to target immunosuppressive macrophages in advanced cancers. To date, Pathios has secured a total of US$33M in Series A funding from the leading venture capital firms, Canaan Partners and Brandon Capital. Pathios is headquartered at the Innovation Centre on Milton Park, a critical science precinct south of Oxford, UK.

For more information: https://pathiostherapeutics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.